Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol n-of-1 series in Gaucher disease type 3
NL-OMON60624Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ambroxol in Gaucher disease type 3, sponsored by Amsterdam University Medical Center. Primary endpoint: Change in cerebrospinal fluid Lyso-GL1. Started Nov 2024; status: recruiting.
02
Drugs
ambroxol
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NL-OMON60624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60624.